DelveInsight has launched a new report on “AL Amyloidosis Pipeline”
Amyloidosis is a rare disease resulting from abnormal protein deposits, called amyloid, in the body’s various tissues. Depending on the particular amyloid structure, the protein can accumulate in an isolated tissue or be widespread, affecting numerous organs and tissues. There are over 30 different amyloid proteins. Each amyloid protein is arranged in a structure called a fibril—low molecular weight proteins derived from precursor proteins. Fibrils of amyloid can float in the plasma of blood and deposit into tissues of the body.
Request for free sample copy- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight
AL Amyloidosis Pipeline analysis across different stages of development (Phase I, II, and III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key competitors, launch date along with product development activities
AL Amyloidosis Pipeline
The current therapeutic approach to systemic amyloidosis is based on the observations that organ dysfunction improves, and survival increases if the synthesis of the amyloidogenic protein precursor is halted. Therefore, the aim of therapy in AL amyloidosis is to reduce the supply of amyloidogenic monoclonal light chains rapidly by suppressing the underlying plasma cell dyscrasia. Decisions about specific treatment regimens for individual patients must consider the balance between anticipated treatment efficacy and tolerability.
Emerging therapies included in the report
AL Amyloidosis Emerging Therapy
The available therapeutics treatment options in AL amyloidosis landscape aim to slow the disease progression and not stop the disease to improve survival benefits. In order to overcome the drawbacks of the treatment, a few companies are working robustly to identify the cause of disease and targeted therapy. Four major drugs are expected to enter the market by 2030.
AL Amyloidosis Emerging Therapy Assessment
Cardiac involvement commonly manifests as heart failure. Renal involvement usually presents as nephrotic syndrome with progressive worsening of renal functions. Thus, a significant cost burden is associated with the consequences of AL amyloidosis. There is a high rate of heart failure in patients with cardiac involvement, and the cost of a heart-failure related hospitalization is expensive but overshadowed by the high cost of heart transplant (the mean costs to Medicare per heart failure patient ranged from USD 28,766 to USD 36,216).
Patients with renal involvement may require dialysis and, eventually, kidney transplant, depending on the effectiveness of disease treatment and/or the need for pre-treatment transplants.
AL Amyloidosis Report Highlights
Table of content
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/